MQS Management’s Mirum Pharmaceuticals MIRM Stock Holding History

MQS Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,902	Closed	-$229K	–	511
2025 Q4	$229K	Buy	+2,902	New	+$208K	0.14%	324

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

MQS Management's MIRM Position: Q1 2026 in Review

MQS Management sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 2,902 shares — an estimated $229K sold.

MQS Management first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $229K in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

MQS Management reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
MQS Management sold 2,902 Mirum Pharmaceuticals shares in Q1 2026, an estimated $229K.
MQS Management first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
MQS Management's Mirum Pharmaceuticals position peaked at $229K in Q4 2025.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on MQS Management's 13F filing for Q1 2026, filed 23 Apr 2026.